The effects of pioglitazone on cerebrovascular resistance in patients with type 2 diabetes mellitus

Metabolism: Clinical and Experimental

Volumn 56, Issue 8, 2007, Pages 1081-1086

  Park, Jong Suk ^a,b   Cho, Min Ho ^a,b   Lee, Kyung Yul ^a,b   Kim, Chul Sik ^a,b   Kim, Hai Jin ^a,b   Nam, Ji Sun ^a,b   Ahn, Chul Woo ^a,b   Cha, Bong Soo ^a,b   Lim, Sung Kil ^a,b   Kim, Kyung Rae ^a,b   Lee, Hyun Chul ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Hallym University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLICLAZIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; TRIACYLGLYCEROL;

ADULT; AGED; ARTERY INTIMA PROLIFERATION; ARTICLE; CEREBROVASCULAR DISEASE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HUMAN; IMAGING SYSTEM; INSULIN RESISTANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

AGED; BASILAR ARTERY; BLOOD GLUCOSE; BODY MASS INDEX; CAROTID ARTERIES; CEREBROVASCULAR CIRCULATION; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; MIDDLE CEREBRAL ARTERY; THIAZOLIDINEDIONES; ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL; VASCULAR RESISTANCE;

EID: 34347393871     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2007.03.017     Document Type: Article

References (30)

1. Kannel W.B., and McGee D.L. Diabetes and cardiovascular disease; the Framingham study. JAMA 241 (1979) 2035-2038
2. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 351 (2004) 1106-1108
3. Barbier O., Torra I.P., Duguay Y., et al. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 22 (2002) 717-726
4. Martens F.M., Visseren F.L., Lemay J., De Koning E.J., and Rabelink T.J. Metabolic and additional vascular effects of thiazolidinediones. Drugs 62 (2002) 1463-1480
5. Mercuri M., Bond M.G., Nichos F.T., et al. Baseline reproducibility of B-mode ultrasound imaging measurements of carotid intimal media thickness. J Cardiovasc Diagn Proced 11 (1993) 241-252
6. Chambless L.E., Heiss G., Folsom A.R., et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors; the ARIC study, 1987-1993. Am J Epidemiol 146 (1997) 483-494
7. Hodis H.N., Mack W.J., LaBree L., et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 128 (1998) 262-269
8. O'Leary D.H., Polak J.F., Kronmal R.A., Manolio T.A., Burke G.L., and Wolfson S.K. Cardiovascular health study collaborative research group: Carotid artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 340 (1999) 14-22
9. Langenfeld M.R., Forst T., Hohberg C., et al. Pioglitazone decrease carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus. Circulation 111 (2005) 2525-2531
10. Nakamura T., Matsuda T., Kawagoe Y., et al. Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. Metabolism 53 (2004) 1382-1386
11. Pfutzner A., Marx N., Lubben G., et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 45 (2005) 1925-1931
12. Koshiyama H., Shimono D., Kuwamura N., Minamikawa J., and Nakamura Y. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 86 (2001) 3452-3456
13. Meigs J.B., Nathan D.M., D'Agostino R.B., and Wilson P.W. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 25 (2002) 1845-1850
14. Amos A.F., McCarty D.J., and Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 14 (1997) S7-S85
15. 123I-p-iodoamphetamine with single photon emission computed tomography. J Diabetes Complications 4 (1990) 170-174
16. Jimenez-Bonilla J.F., Carril J.M., Quirce R., Gomez-Barquin R., Amado J.A., and Gutierrez-Mendiguchia C. Assessment of cerebral blood flow in diabetic patients with no clinical history of neurological disease. Nucl Med Commun 17 (1996) 790-794
17. Rodriguez G., Nobili F., Celestino M.A., et al. Regional cerebral blood flow and cerebrovascular reactivity in IDDM. Diabetes Care 16 (1993) 462-483
18. Mortel K.F., Meyer J.S., Sims P.A., and McClintic K. Diabetes mellitus as a risk factor for stroke. South Med J 83 (1990) 904-911
19. Grill V., Gutniak M., Bjorkman O., et al. Cerebral blood flow and substrate utilization in insulin-treated diabetic subjects. Am J Physiol 258 (1990) 813-820
20. Lee K.Y., Sohn Y.H., Baik J.S., Kim G.W., and Kim J.S. Arterial pulsatility as an index of cerebral microangiopathy in diabetes. Stroke 31 (2000) 1111-1115
21. Bonora E., Moghetti P., Zancanaro C., Cigolini M., Querena M., and Cacciatori V. Estimates of in vivo insulin action in man; comparison of insulin tolerance tests with euglycemic and hyperglycemic glucose clamp studies. J Clin Endocrinol Met 68 (1989) 374-378
22. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
23. Roberts A.W., Thomas A., Rees A., and Evans M. Peroxisome proliferator-activated receptor-r agonists in atherosclerosis: Current evidence and future directions. Curr Opin Lipidol 14 (2003) 567-573
24. Tham D.M., Wang Y.X., and Rutledge J.C. Modulation of vascular inflammation by PPARs. Drug News Perspect 16 (2003) 109-116
25. Derosa G., Cicero A.F., Gaddi A., et al. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract 69 (2005) 5-13
26. Boyle P.J., King A.B., Olansky L., Marchetti A., Lau H., and Martin J. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther 24 (2002) 378-396
27. Miyazaki Y., Mahankali A., Matsuda M., et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24 (2001) 710-719
28. Yamanouchi T., Sakai T., Lgarashi K., Ichiyanagi K., Watanabe H., and Kawasaki T. Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabet Med 22 (2005) 980-985
29. Shimazu T., Inoue I., Araki N., et al. A peroxisome proliferator-activated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia. Stroke 36 (2005) 353-359
30. Sundararajan S., Gamboa J.L., Victor N.A., Wanderi E.W., Lust W.D., and Landreth G.E. Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience 130 (2005) 685-696